ResearcherUniversity of Tennessee Health Science CenterNo recent work listed

Michael K. Danquah

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7408-3951; OpenAlex author ID A5040370583. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2012: 2 papers

Papers 2

Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Co-author DOI 10.1021/mp3002792 ↗
Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Co-author DOI 10.1517/17425247.2012.722079 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Stephen W. Behrman · 2 shared papers, 2012 · strength 0.08
- Paper Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. DOI 10.1517/17425247.2012.722079 ↗
- Paper Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. DOI 10.1021/mp3002792 ↗
Ram I. Mahato · 2 shared papers, 2012 · strength 0.08
- Paper Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. DOI 10.1517/17425247.2012.722079 ↗
- Paper Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. DOI 10.1021/mp3002792 ↗
Deepak Chitkara · 1 shared paper, 2012 · strength 0.03
- Paper Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. DOI 10.1021/mp3002792 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.